Metabolic effects of PCSK9 inhibition with Evolocumab in subjects with elevated Lp(a)

Overview of attention for article published in Lipids in Health and Disease, May 2020

Altmetric Badge

About this Attention Score

Good Attention Score compared to outputs of the same age (67th percentile)
Good Attention Score compared to outputs of the same age and source (75th percentile)

So far, Altmetric has seen 6 X posts from 6 X users, with an upper bound of 8,431 followers.

RT @dan_soffer: Mechanistic potential for PCSK9 mAb's in patients with high Lp(a) and nonHDLc/TGs https://t.co/xfOfT8xcIL

Mechanistic potential for PCSK9 mAb's in patients with high Lp(a) and nonHDLc/TGs https://t.co/xfOfT8xcIL

RT @XiangZhang18: Our latest @NgaleHealth #metabolomics study showed that the #PCSK9 inhibitor Evolocumab @Amgen markedly affected VLDL met…

RT @XiangZhang18: Our latest @NgaleHealth #metabolomics study showed that the #PCSK9 inhibitor Evolocumab @Amgen markedly affected VLDL met…

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity, including 2 additional X posts.